FRA/JNJ0 (FRA/JNJ0)

Frankfurt Stock Exchange: FRA/JNJ0 · EUR

€21.6

+0.40 (+1.9%)· Recorded snapshot

Market cap	580.6B
Revenue (ttm)	87.2B
Net income (ttm)	14.1B
EPS (ttm)	€0.39
P/E (trailing)	54.7x
P/E (forward)	23.8x
Dividend	€0.42 (1.96%)
Volume	0

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 87.2B
Net income (ttm): 14.1B
EPS (ttm): €0.39
P/E (trailing): 54.7x
P/E (forward): 23.8x
Market cap: 580.6B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E23.8

P25 n/aP50 n/aP75 n/a

Trailing P/E54.7

P25 n/aP50 n/aP75 n/a

ROE20

P25 n/aP50 n/aP75 n/a

ROIC21.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All FRA/JNJ0 indicators

Market & fundamental data

Available fields

237

Groups with data

Currency

USD

Showing 237 of 237 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	DE
Earnings date	2026-10-13
Employees	138,200
Employees change	100
Employees growth	0.07%
Enterprise value	EUR 605.2B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
Financial report date	2026-09-27
First seen	2026-09-02
Fiscal year end	December
Founded	1886
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	CA47817E1034
Last earnings date	2026-10-13
Last refreshed	2026-10-28
Market cap	EUR 580.6B
Next earnings date	2027-01-19
Price	EUR 21.60
Price currency	EUR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-27
Symbol	fra/JNJ0
Website	https://www.jnj.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	46.5x
Average P/E ratio (3Y)	20.72x
Average P/E ratio (5Y)	22.21x
Earnings yield	1.83%
EV/Earnings	42.85x
EV/EBIT	25.53x
EV/EBITDA	19.43x
EV/FCF	33.5x
EV/Sales	6.79x
FCF / EV yield	2.99%
FCF yield	3.11%
Forward P/E	23.84x
Graham number	5.60933
Graham upside	-74.03%
Lynch fair value	EUR 2.63
Lynch upside	-87.84%
P/(FCF - SBC) ratio	34.52x
P/(OCF - SBC) ratio	26.75x
P/B ratio	8.12x
P/E ratio	54.73x
P/FCF ratio	32.14x
P/OCF ratio	25.29x
P/S ratio	6.66x
Price/EBITDA ratio	19.18x
Sector forward P/E	14.8x
Sector P/E	39.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	26.59%
EBITDA margin	34.73%
Effective tax rate	9.26%
FCF margin	20.23%
Gross margin	67.77%
Operating margin	26.59%
Pretax margin	17.86%
Profit margin	16.2%
Profit per employee	EUR 102,195
Profitable quarters	14
Profitable years	35
Revenue per employee	EUR 630,727
ROA	8.46%
ROA (5Y)	8.04%
ROCE	18.6%
ROE	20.02%
ROE (5Y)	24.21%
ROIC	21.57%
ROIC (5Y)	23.67%
SBC / revenue	1.43%
Tax / revenue	1.65%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-36.37%
EPS growth (Q)	-95.89%
EPS growth (QoQ)	-96.16%
EPS growth 10Y	1.46%
EPS growth 3Y	-20.75%
EPS growth 5Y	-0.32%
EPS growth years	1
FCF growth	5.07%
FCF growth (Q)	-20.64%
FCF growth (QoQ)	-12.84%
FCF growth 3Y	9.37%
FCF growth 5Y	-1.72%
Gross profit growth	6.88%
Gross profit growth (Q)	3.56%
Gross profit growth 3Y	5.04%
Gross profit growth 5Y	1.75%
Net income growth	-35.93%
Net income growth (Q)	-95.92%
Net income growth (QoQ)	-96.21%
Net income growth 3Y	-22.54%
Net income growth 5Y	-2.08%
Net income growth years	1
OCF growth	8.08%
OCF growth (Q)	-15.8%
OCF growth (QoQ)	-10.4%
OCF growth 10Y	4.28%
OCF growth 3Y	8.86%
OCF growth 5Y	0.11%
Operating income growth	7.65%
Operating income growth (Q)	-9.78%
Operating income growth 3Y	3.06%
Operating income growth 5Y	1.65%
Revenue growth	7.8%
Revenue growth (Q)	5.86%
Revenue growth (QoQ)	0.35%
Revenue growth 10Y	3.33%
Revenue growth 3Y	5.87%
Revenue growth 5Y	1.67%
Revenue growth quarters	13
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -4.9B
Depreciation and amortization	EUR 7.3B
EBIT	EUR 23.2B
EBITDA	EUR 30.3B
EPS	EUR 0.39
Financing cash flow	EUR -15.9B
Free cash flow	EUR 18.1B
Free cash flow minus SBC	EUR 16.8B
Gross profit	EUR 59.1B
Income taxes	EUR 1.4B
Investing cash flow	EUR -8.2B
Net borrowing	EUR -707.5M
Net cash flow	EUR -1.2B
Net income	EUR 14.1B
Operating cash flow minus SBC	EUR 21.7B
Operating income	EUR 23.2B
Revenue	EUR 87.2B
Stock-based compensation	EUR 1.2B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.03
Book value per share	EUR 29.72
Debt / EBITDA	1.29
Debt / equity	0.55
Debt / FCF	2.17
Goodwill	EUR 43.6B
Interest coverage	26.84
Long-term assets	EUR 122.6B
Long-term liabilities	EUR 51.8B
Net cash (debt)	EUR -24.1B
Net cash / market cap	-4.14%
Net debt / EBITDA	0.79
Net debt / equity	0.34
Net debt / FCF	1.33
Piotroski F-Score	6
Property, plant and equipment	EUR 21.7B
Shareholders' equity	EUR 71.5B
Tangible book value	EUR -11.9B
Tangible book value per share	EUR -4.96
Total assets	EUR 173.2B
Total cash	EUR 15.1B
Total debt	EUR 39.2B
Total liabilities	EUR 101.7B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.51
Current assets	EUR 50.7B
Current liabilities	EUR 49.9B
Current ratio	1.02
Inventory turnover	2.17
Net working capital	EUR -6.6B
Quick ratio	0.65
Working capital	EUR 784.5M
Working capital turnover	37.6

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.8%
Dividend growth	-0.49%
Dividend growth years	0
Dividend payment date	2026-12-15
Dividend payment years	4
Dividend payout frequency	Quarterly
Dividend per share	EUR 0.42
Dividend yield	1.96%
Ex-dividend date	2026-11-24
Last dividend	EUR 0.11
Payout ratio	79.01%
Shareholder yield	1.17%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 19.58
1D price change	1.89%
1W price change	2.91%
1W total return	2.91%
1Y price change	40.4%
1Y return CAGR	42.89%
1Y total return	42.85%
20-day SMA	EUR 20.42
200-day SMA	EUR 19.36
3M price change	3.92%
3M total return	3.92%
3Y price change	53.62%
3Y return CAGR	18.59%
3Y total return	66.8%
50-day SMA	EUR 20.85
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 22.20
52-week high date	2026-10-27
52-week low	EUR 14.50
52-week low date	2025-11-10
6M price change	16.48%
6M total return	17.16%
All-time high	EUR 22.20
All-time high date	2026-09-04
All-time low	EUR 11.80
All-time low date	2025-04-09
Average true range (ATR)	EUR 0.42
Average volume	0.6
Change from 52-week high	-2.7%
Change from 52-week low	48.97%
Change from all-time high	-4.5%
Change from all-time low	79.66%
Change from open	1.89%
Day's gap	0%
High price	EUR 22.20
Low price	EUR 21.20
Monthly RSI	72.7
Open price	EUR 21.20
Position in 52-week range	40%
Previous close	EUR 21.20
Price vs 150-day SMA	8.3%
Price vs 20-day SMA	3.82%
Price vs 200-day SMA	9.48%
Price vs 50-day SMA	1.69%
Relative volume	20
RSI	62.17
Sharpe ratio	1.28
Sharpe ratio (3Y)	0.62
Sortino ratio	2.18
Sortino ratio (3Y)	1.15
Volume	0
Weekly RSI	61.39
YTD price change	30.86%
YTD total return	32.31%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2.4B
Shares change (QoQ)	0.35%
Shares change (YoY)	0.8%
Shares held by insiders	0.04%
Shares held by institutions	76.32%
Short ratio	2.4 days

Deeper analysis on FRA/JNJ0

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this FRA/JNJ0 report

Is a complete FRA/JNJ0 research report available?

No complete published report is available for fra/JNJ0 (FRA/JNJ0) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

FRA/JNJ0 (FRA/JNJ0)

Price

Financial snapshot

Fair-value bridge

Latest news · FRA/JNJ0

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All FRA/JNJ0 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on FRA/JNJ0

Frequently asked questions